Revenue for the three-quarter period rose to ¥597 million, up from the ¥563 million recorded during the same timeframe a year earlier. Despite this top-line growth, the company’s bottom line was weighed down by non-operating expenses, causing the net loss to deepen from the ¥717 million deficit reported in the previous year.

Shifting Margins and Per-Share Data

According to the company's financial filing, the operating loss showed a marginal improvement, narrowing to ¥694 million from ¥698 million. However, the pretax loss expanded to ¥720 million, signaling continued pressure on the firm’s financial health as it navigates the capital-intensive drug discovery sector.

Key metrics from the nine-month report include:

• Total Revenue: ¥597 million
• Net Loss: ¥783 million
• Loss per Share: ¥2.52

The results, calculated under Japanese accounting standards, show a notable improvement in loss per share—falling from ¥2.78 to ¥2.52—despite the larger total net loss. This discrepancy typically indicates a change in the number of outstanding shares during the fiscal period. OncoTherapy Science remains entrenched in the high-risk, high-reward field of oncology research, where development costs often outpace commercial gains in the early stages of the pipeline.